Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | KDM5A | P29375 | 3/20 | 0.45 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8392478 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL2752775 | 0.98 | SIGMAR1 (0.46) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL9203 | 0.93 | SIGMAR1 (0.54) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL931403 | 0.93 | SIGMAR1 (0.54) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL8392784 | 0.93 | ALOX5 (0.43) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL13520 | 0.91 | SIGMAR1 (0.57) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL9718136 | 0.91 | SIGMAR1 (0.57) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL11010082 | 0.91 | SIGMAR1 (0.57) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL8860844 | 0.91 | SIGMAR1 (0.57) | SIGMAR1CYP1A2HPGDALOX5KDM5A | |
| SCHEMBL20408333 | 0.91 | SIGMAR1 (0.57) | SIGMAR1CYP1A2HPGDALOX5KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917907-B1 | MODULATORS OF POTASSIUM ION CHANNELS AND USES THEREOF | UNIV DEGLI STUDI DI SALERNO (IT) | 2025-05-21 | — | — | EP | claimed |
| CN-107567445-A | It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor | 坎塞拉有限公司 | 2018-01-09 | — | — | CN | claimed |
| US-7595403-B2 | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | claimed |
| US-20060276522-A1 | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors | ELI LILLY AND COMPANY (US) | 2006-12-07 | — | — | US | claimed |
| US-7045634-B2 | Prostamide receptor antagonists | ALLERGAN, INC. (US) | 2006-05-16 | — | — | US | claimed |
| EP-1615900-A1 | BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2005026172-A1 | PROSTAMIDE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050054699-A1 | Prostamide receptor antagonists | ALLERGAN, INC. | 2005-03-10 | — | — | US | claimed |
| WO-2004094394-A1 | BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | claimed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | claimed |
| CN-116218464-A | Adhesive for improving adhesive property of rubber and copper-plated steel wire and preparation method thereof | 江苏国立化工科技有限公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-03-23 | — | — | US | disclosed |
| US-20050054699-A1 | Prostamide receptor antagonists | ALLERGAN, INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2004094394-A1 | BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054699-A1 | Prostamide receptor antagonists | PTGIR, PTGER1, TBXA2R | SIGMAR1 476/4885CYP1A2 412/4885HPGD 206/4885 |
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | SIGMAR1 3444/4885CYP1A2 760/4885HPGD 352/4885 |
| US-20060276522-A1 | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors | LIPG, PNLIP, LIPC | SIGMAR1 3000/4885CYP1A2 2235/4885HPGD 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.